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Background:  Previous  studies  showed  that  nicorandil  can  reduce  coronary  events  in  patients
with coronary  artery  disease.  However,  it  is  unclear  whether  oral  nicorandil  treatment  may
reduce mortality  following  acute  myocardial  infarction  (AMI).
Methods  and  Results:  We  examined  the  impact  of  oral  nicorandil  treatment  on  cardiovascu-
lar events  in  1846  AMI  patients  who  were  hospitalized  within  24  h  after  AMI  onset,  treated
with emergency  percutaneous  coronary  intervention  (PCI),  and  discharged  alive.  Patients
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were  divided  into  those  with  (Group  N,  n  =  535)  and  without  (Group  C,  n  =  1311)  oral  nicorandil
treatment  at  discharge.  No  signiﬁcant  differences  in  age,  gender,  body  mass  index,  prevalence  of
coronary  risk  factors,  or  history  of  myocardial  infarction  existed  between  the  two  groups;  how-
ever, higher  incidences  of  multi-vessel  disease,  and  a  lower  rate  of  successful  PCI  were  observed
in Group  N.  During  the  median  follow-up  of  709  (340—1088)  days,  all-cause  mortality  rate  was  43%
lower in  Group  N  compared  with  Group  C  (2.4%  vs.  4.2%,  stratiﬁed  log-rank  test:  p  =  0.0358).  Mul-
tivariate Cox  regression  analysis  revealed  that  nicorandil  treatment  was  associated  with  all-cause
death after  discharge  (Hazard  ratio  0.495,  95%  CI:  0.254—0.966,  p  =  0.0393),  but  not  for  other
cardiovascular  events  such  as  re-infarction,  admission  for  heart  failure,  stroke  and  arrhythmia.
Conclusions:  The  results  suggest  that  oral  administration  of  nicorandil  is  associated  with  reduced
ting  of  secondary  prevention  after  AMI.
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are  presented  as  numbers  or  percentages.  Differences  of
continuous  variables  between  groups  were  assessed  using
the  Student’s  t-test,  whereas  categorical  variables  wereincidence  of  death  in  the  set
© 2011  Japanese  College  of  C
Introduction
Although  recent  progress  in  the  management  of  acute
myocardial  infarction  (AMI)  has  decreased  mortality  [1—3],
long-term  mortality  remains  high  in  post-AMI  patients  [4].
To  further  decrease  mortality  rates  in  the  clinical  setting
after  AMI,  numerous  efforts  have  been  directed  towards
the  pharmacological  modiﬁcation  of  left  ventricular  (LV)
performance  and  remodeling,  as  well  as  stabilization  of
atherosclerotic  coronary  plaques,  as  it  has  been  shown  to
be  associated  with  prognosis  [5].  In  this  context,  the  anti-
anginal  drug  nicorandil  is  one  of  the  promising  candidates
for  improving  outcomes  of  post-AMI  patients  due  to  its  car-
dioprotective  properties  [6—19].
Nicorandil  is  a  nicotinamide  ester  that  possesses  K-
ATP  channel-activating  and  nitrate-like  properties  and  is
being  increasingly  used  to  treat  coronary  artery  disease
(CAD).  Nicorandil  relieves  symptoms  of  ischemia  and  also
has  numerous  cardioprotective  properties,  such  as  phar-
macological  preconditioning  [6—8], restoration  of  cardiac
blood  ﬂow  to  ischemic  and  no-reﬂow  myocardium  [9—13],
prevention  of  Ca2+ overload  [14,15],  and  attenuation  of
cardiac  sympathetic  nerve  injury  [16—18], and  so  on.  How-
ever,  although  the  effects  of  nicorandil  in  protection  of  the
myocardium  during  acute  ischemic  injury  have  been  exten-
sively  reported  in  the  clinical  setting  [9—13,17,20—25], little
is  known  about  the  long-term  impacts  of  nicorandil  on  mor-
tality  and  secondary  complications  after  AMI  [18,26].
In  the  present  study,  we  examined  the  mortality  impact
of  oral  nicorandil  at  discharge  using  a  relatively  large  patient
cohort  in  the  setting  of  secondary  prevention  after  AMI.
Methods
The  Osaka  acute  coronary  insufﬁciency  study
(OACIS)
The  Osaka  acute  coronary  insufﬁciency  study  (OACIS)  is
a  prospective,  multi-center  observational  study  designed
to  collect  and  analyze  demographic,  procedural,  outcome
data,  and  blood  samples  in  patients  with  AMI  at  25  collab-
orating  hospitals  in  the  Osaka  region  of  Japan  [3,27—30].
As  part  of  the  OACIS,  research  cardiologists  and  special-
ized  research  nurses  recorded  data  on  socio-demographic
variables,  medical  histories,  therapeutic  procedures,  and
clinical  events  during  patient  hospitalization,  and  also
obtained  follow-up  clinical  data  at  3,  6,  and  12  months
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fter  the  occurrence  of  AMI,  and  annually  thereafter.  Infor-
ation  was  obtained  from  hospital  medical  records  and  by
irect  interviews  with  patients,  their  family  members,  and
heir  treating  physicians.  All  data  were  transmitted  to  the
ata  collection  center  at  the  Department  of  Cardiovascu-
ar  Medicine,  Osaka  University  Graduate  School  of  Medicine,
uita,  Japan  for  processing  and  analysis.  The  diagnosis  of  AMI
equired  the  presence  of  two  of  the  following  three  crite-
ia:  (1)  history  of  central  chest  pressure,  pain,  or  tightness
asting  more  than  30  min,  (2)  ST-segment  elevation  0.1  mV
n  1  limb  lead  or  2  precordial  leads,  and  (3)  an  increase  in
erum  creatine  kinase  (CK)  concentration  of  two  times  the
pper  limit  of  normal.
atients
mong  the  patients  registered  with  the  OACIS  registry,  1846
onsecutive  patients  fulﬁlling  the  following  criteria:  (1)
dmission  within  24  h  after  the  onset  of  AMI  between  January
005  and  March  2009,  (2)  treatment  with  emergency  per-
utaneous  coronary  intervention  (PCI)  on  admission,  and
3)  survival  discharge,  were  enrolled  in  the  study.  Of  these
atients,  535  were  treated  with  oral  nicorandil  at  discharge
Group  N),  while  the  remaining  1311  patients  did  not  receive
icorandil  at  discharge  (Group  C).
linical  endpoints
he  demographic  and  clinical  data  and  the  primary  end-
oints  during  the  ﬁve-year  period  following  discharge,
ll-cause  mortality,  non-fatal  re-infarction,  re-admission
or  heart  failure,  and  coronary  revascularization,  includ-
ng  PCI  and  coronary  artery  bypass  grafting,  were  compared
etween  patients  in  Groups  N  and  C.
tatistical  analysis
esults  are  expressed  as  medians  (25th  and  75th  percentiles)
r  mean  ±  SD  for  continuous  variables,  and  qualitative  dataompared  using  the  chi-square  test.  Factors  inﬂuencing
ortality  were  analyzed  using  a  multivariate  Cox  pro-
ortional  hazard  regression  model  with  14  variables  from
ajor  patient  backgrounds  and  treatments  to  minimize
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Figure  1  Kaplan—Meier  plots  for  mortality  during  the  ﬁve-
year follow-up  period  following  discharge  for  AMI.  p  value  after
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endpoints,  including  cardiac  death  (56%),  fatal  myocardialdjustment  with  variables  that  had  p  values  of  <0.1  in  the  mul-
ivariate  cox  proportional  hazard  model  is  <0.05.
he  effect  of  co-founders.  Variables  included  in  the  model
ere  age,  gender,  obesity,  diabetes,  hypertension,  dys-
ipidemia,  smoking,  multi-vessel  disease,  PCI  success,  and
rescription  of  statins,  renin  angiotensin  system  inhibitors,
r  beta-blockers.  Survival  curves  were  constructed  using  the
aplan—Meier  method,  and  the  signiﬁcance  of  differences
n  survival  was  assessed  using  the  stratiﬁed  log-rank  test
ith  variables  as  strata  suggested  by  Cox  regression.  Analy-
is  was  performed  using  SAS  version  9.1.3  for  Windows  (SAS
nc.,  Cary,  NC)  and  PASW  Statistics,  version  18.0  (SPSS  Inc.,
hicago,  IL).  For  all  analyses,  statistical  signiﬁcance  was  set
t  p  <  0.05.
esults
he  study  population  consisted  of  535  patients  who  received
icorandil  at  discharge  (Group  N)  and  1311  patients  who  did
ot  (Group  C).  The  patient  baseline  characteristics,  includ-
ng  the  cardiovascular  medications  being  taken  before  and
uring  the  study,  are  summarized  in  Table  1.  No  signiﬁcant
ifferences  in  age,  gender,  body  mass  index,  prevalence
f  coronary  risk  factors  of  diabetes,  hypertension,  dys-
ipidemia,  obesity  and  smoking,  or  history  of  myocardial
nfarction  were  found  between  the  two  groups.  However,  a
igher  incidence  of  multi-vessel  disease  and  treatment  with
ntra-aortic  balloon  pumping,  and  a  lower  rate  of  success-
ul  PCI,  deﬁned  as  presence  of  TIMI3  ﬂow  grade  after  the
rocedures,  were  noted  in  Group  N,  suggesting  that  Group
 included  patients  with  more  severe  clinical  conditions.
The  median  follow-up  period  was  709  (340—1088)  days.
uring  the  follow-up  period,  the  all-cause  mortality  rate  was
3%  lower  in  Group  N  compared  with  Group  C,  although  this
ifference  was  not  signiﬁcant  (2.4%  vs.  4.2%,  log-rank  test:
 =  0.0849).  However,  multivariate  Cox  proportional  hazard
nalysis  revealed  that  several  variables  were  correlated  with
ortality  following  discharge  of  the  AMI  patients.  After
djustment  with  the  variables,  Kaplan—Meier  curves  for
ortality  showed  a  signiﬁcant  difference  between  Groups
 and  C  (stratiﬁed  log-rank  test:  p  =  0.0358,  Fig.  1).
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Despite  the  fact  that  patients  of  both  groups  were  also
dministered  other  secondary  prevention  drugs,  nicorandil
as  the  only  drug  to  have  an  association  with  decreased
ortality  (Table  2).  Multivariate  Cox  proportional  hazard
nalysis  revealed  that  nicorandil  treatment  was  a  pre-
ictor  for  all-cause  death  after  discharge  (Hazard  ratio
HR)  0.495,  95%  CI:  0.254—0.966,  p  =  0.039),  but  not  for
e-infarction,  admission  for  heart  failure,  arrhythmia  and
troke  (Table  3).  Subgroup  analysis  revealed  that  no  sig-
iﬁcant  interaction  were  detected  between  the  impact  of
icorandil  and  variables  of  age,  gender,  diabetes,  hyper-
ension,  dyslipidemia,  multi-vessel  disease,  PCI  success,
nd  peak  CK  levels  (Table  4),  suggesting  that  nicorandil
reatment  displayed  a  signiﬁcant  reduction  in  mortality
egardless  of  the  subgrouping.  In  addition,  subgroup  analy-
is  also  suggested  that  nicorandil  treatment  was  particularly
ssociated  with  reduced  mortality  for  patients  with  ages  of
75  y.o.,  with  hypertension,  or  of  male  gender  (Table  4).
iscussion
his  is  the  ﬁrst  study  suggesting  a  mortality  beneﬁt  of
icorandil  for  post-AMI  patients  in  the  clinical  setting.
n  this  retrospective  analysis  with  a  relatively  large-scale
MI  cohort,  we  have  demonstrated  that  AMI  patients  who
eceived  oral  nicorandil  treatment  displayed  a  reduction
n  all-cause  mortality  during  a  ﬁve-year  follow-up  period.
ur  results  suggest  that  nicorandil  may  have  the  potential
o  improve  survival  outcomes  in  the  setting  of  secondary
revention  after  AMI.
The  most  important  ﬁnding  of  the  present  study  is  that
icorandil  treatment  was  associated  with  a  nearly  50%
eduction  in  all-cause  mortality  following  discharge  for  AMI
HR  0.495,  95%  CI:  0.254—0.966,  p  =  0.0393).  This  ﬁnding  also
upports  the  results  of  a  recent  large-scale  randomized  con-
rol  study,  the  Impact  of  Nicorandil  in  Angina  [IONA]  study
31],  and  a  retrospective  sub-analysis  of  the  Japanese  Coro-
ary  Artery  Disease  (JCAD)  study  [32], which  suggested  that
icorandil  had  a  beneﬁcial  impact  on  mortality  and  morbid-
ty  in  CAD  patients.  In  the  IONA  study,  a  20  mg  twice-daily
ral  nicorandil  treatment  group  (N  =  2565)  displayed  a  signif-
cant  reduction  in  all  cardiovascular  events  over  a  placebo
roup  (N  =  2561)  [31]. In  addition,  the  nicorandil  group  had  a
rend  of  reduced  mortality  compared  to  the  placebo  group
4.3%  vs.  5.0%,  respectively;  HR  0.85,  p  =  0.222),  although
he  difference  was  not  statistically  signiﬁcant,  likely  due
o  the  relatively  short  follow-up  period  (mean:  1.6  years).
he  JCAD  study  is  a  large  multicenter  collaborative  prospec-
ive  observational  study  designed  to  investigate  risk  factors,
edication  use,  and  outcomes  of  CAD  patients  in  Japan
N  =  13,812)  [33]. In  a  retrospective  analysis  of  the  JCAD
tudy,  Horinaka  et  al.  [32]  compared  the  incidence  of  cardio-
ascular  events  between  2558  nicorandil-treated  and  2558
ontrol  patients  (mean  follow-up:  2.7  years)  in  the  JCAD
ohort  and  revealed  that  death  from  all  causes  (primary  end-
oint)  was  35%  lower  (HR  0.65,  p  =  0.0008)  in  the  nicorandil
roup.  Further,  marked  reductions  in  several  secondarynfarction  (56%),  cerebral  or  vascular  death  (71%),  and  con-
estive  heart  failure  (33%),  were  noted  in  the  nicorandil
roup  [32]. Taken  together,  these  lines  of  evidence  suggest
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Table  1  Patient  characteristics  of  the  nicorandil  (Group  N)  and  non-nicorandil  (Group  C)  groups.
Variable  Group  C  (n  =  1311)  Group  N  (n  =  535)  p  Value
Age  (years) 65.7  ±  12.1  66.2  ±  11.8  0.388
Male 990  (75.5%)  411  (76.8%)  0.589
Symptom to  admission  time  (h)  5.2  ±  5.5  4.9  ±  5.5  0.255
STEMI 1129  (86.8%)  467  (87.5%)  0.76
Killip class  >1 1067  (85.3%) 429  (82.7%) 0.192
Cardiac pulmonary  arrest 38  (2.9%) 12  (2.2%) 0.528
Peak creatine  kinase  (U/L) 2971  ±  2645 3144  ±  2634 0.223
Serum creatinine  (mg/dL)  1.04  ±  1.16  1.06  ±  1.19  0.752
Common comorbidities
Obesity  405  (32.6%)  174  (33.5%)  0.739
Diabetes mellitus 416  (31.7%)  192  (35.9%)  0.091
Hypertension  838  (65.5%)  342  (65.9%)  0.913
Dyslipidemia  557  (44.3%)  250  (48.3%)  0.142
Smoking history  786  (60.9%)  328  (62.4%)  0.595
Previous MI  149  (11.5%)  58  (11.0%)  0.807
Angiographic  information
Initial  TIMI  grade  0.484
0 754  (57.8%)  304  (57.3%)
1 142  (10.9%)  54  (10.2%)
2 246  (18.9%)  93  (17.5%)
3 163  (12.5%)  80  (15.1%)
Multiple vessel  disease  534  (41.0%)  269  (50.5%)
Collateral  vessels  402  (31.2%)  164  (31.5%)
Infarct related  artery:  LAD  552  (41.8%)  242  (46.0%)
Reperfusion  therapy
PCI  1331  (100%)  535  (100%)  1
Stent 1225  (93.5%)  507  (94.9%)  0.282
Thrombectomy  921  (70.3%)  354  (66.2%)  0.086
Drug-eluting  stent  89  (6.8%)  35  (6.8%)  0.918
PCPS 29  (2.2%)  6  (1.1%)  0.135
IABP 184  (14.0%)  97  (18.1%)  0.032
Emergent CABG  9  (0.7%)  5  (0.9%)  0.563
Temporary pacing  275  (21.3%)  101  (19.3%)  0.371
Successful reperfusion  1217  (93.6%)  481  (91.1%)  0.07
No-reﬂow phenomenon  36  (5.5%)  16  (6.8%)  0.517
Medications  at  discharge
Anti-platelets  1289  (98.3%)  529  (98.9%)  0.529
ACEIs 419  (32.0%)  279  (52.1%)  <0.001
ARBs 647  (49.4%)  175  (32.7%)  <0.001
ACEI and/or  ARB  1038  (79.2%)  435  (81.3%)  0.038
-Blockers 813  (62.0%)  303  (56.6%)  0.036
Statin 689  (52.6%)  298  (55.7%)  0.237
Ca channel  blockers  205  (15.6%)  70  (13.1%)  0.171
Nitrates 255  (19.5%)  91  (17.0%)  0.237
Diuretics 336  (25.6%)  143  (26.7%)  0.64
Results are expressed as mean ± SD for continuous variables. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; CABG, coronary artery bypass graft; IABP, intraaortic balloon pumping; MI, myocardial infarction; PCI, percutaneous coronary
intervention; PCPS, percutaneous cardio-pulmonary support; STEMI, ST elevation myocardial infarction; TIMI, thrombolysis in myocardial
cinfarction.
that  nicorandil  has  a  beneﬁcial  effect  for  reducing  mortality
in  patients  with  CAD,  including  post-AMI  patients.
It  is  noteworthy  that  nicorandil  treatment  at  discharge
was  associated  with  mortality  reduction  (Table  1),  although
nicorandil  had  been  likely  used  as  an  adjunct  to  other
i
p
n
aardioprotective  drugs,  rather  than  as  an  alternative,  which
s  supported  by  the  comparable  prevalence  of  secondary
revention  drugs  between  Groups  N  and  C.  Accordingly,
icorandil  is  potentially  a  good  candidate  to  be  given  in
n  additive  manner  with  popular  cardiovascular  secondary
18  Y.  Sakata  et  al.
Table  2  Predictors  for  death  after  discharge.
Variable  Multivariate  cox  proportional  hazard  model
HR Lower  limit  Upper  limit  p  Value
Statins  0.904  0.516  1.583  0.7247
RAS inhibitors 0.894  0.488  1.638  0.7166
Beta blockers 1.408  0.802  2.470  0.2332
Ca channel  blockers 0.493  0.221  1.102  0.0849
Nicorandil 0.495  0.254  0.966  0.0393
Variables: age, gender, diabetes mellitus, hypertension, dyslipidemia, smoking, multi-vessel disease, successful percutaneous coronary,
intervention, peak creatine kinase level, beta-blockers, renin-, angiotensin inhibitors, statins, calcium channel blockers, and nicorandil.
Table  3  Impact  of  oral  nicorandil  on  cardiac  events.
Cardiovascular  event  HR  95%  CI  p  Value
Death  0.495  (0.254—0.966)  0.039
Myocardial infarction  0.873  (0.469—1.624)  0.667
Admission for  heart  failure  0.741  (0.410—1.338)  0.319
Arrhythmia 0.737  (0.360—1.509)  0.366
Stroke 0.363  (0.107—1.229)  0.103
Variables: age, gender, diabetes mellitus, hypertension, dyslipidemia, smoking, multi-vessel disease, successful percutaneous coronary,
intervention, peak creatine kinase level, beta-blockers, renin-, angiotensin inhibitors, statins, calcium channel blockers, and nicorandil.
Table  4  Predictors  for  death  after  discharge.
Subgroup  N  HR  95%  CI  p  Value  p  for  Interaction
Age  (years) <75  1242  0.294  (0.088—0.984)  0.0471  0.2012
≥75 435  0.817  (0.371—1.797)  0.6145
Gender Female  431  0.792  (0.219—2.866)  0.7224  0.4888
Male 1394  0.474  (0.227—0.991)  0.0472
Diabetes mellitus No  1210  0.481  (0.182—1.269)  0.1391  0.6086
Yes 608  0.610  (0.259—1.438)  0.2587
Hypertension No 618 0.802  (0.215—2.990)  0.7425  0.1672
Yes 1180 0.429  (0.200—0.921)  0.0298
Dyslipidemia No 954  0.542  (0.250—1.173)  0.1199  0.6556
Yes 805  0.308  (0.082—1.152)  0.0802
Multi-vessel  disease No 1006  0.596  (0.205—1.733)  0.3423  0.8772
Yes 803  0.483  (0.213—1.096)  0.0815
PCI success No  130  0.365  (0.041—3.291)  0.3692  0.9888
Yes 1647  0.544  (0.277—1.069)  0.0775
Peak CK  level  (U/L) <3000  1203  0.532  (0.227—1.247)  0.1464  0.7414
≥3000  621  0.530  (0.198—1.418)  0.2061
CK, creatine kinase; PCI, percutaneous coronary intervention.
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frevention  drugs,  such  as  beta-blockers  and/or  rennin-
ngiotensin  system  inhibitors.  It  is  also  noteworthy  that
he  present  study  suggested  that  nicorandil  was  beneﬁcial
or  all  patients  in  the  secondary  prevention  settings  after
MI,  because  no  signiﬁcant  interaction  were  detected  after
ubgroup  analysis  (Table  4).  In  addition,  the  mortality  ben-
ﬁt  of  nicorandil  seemed  particularly  apparent  for  patients
0
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<ith ages  <75  y.o.,  with  hypertension,  and  of  male  gender
Table  4).  Notably,  a  71%  reduction  in  mortality  rate  was
ound  in  nicorandil-treated  patients  with  ages  <75  y.o.  (HR
.294,  95%  CI:  0.088—0.984,  p  =  0.047).  Therefore,  we  sug-
est  that  nicorandil  may  represent  a  potent  ﬁrst-line  drug
or  all  patients  after  AMI,  particularly  for  those  with  ages
75  y.o.,  male  gender,  or  hypertension.
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OOral  treatment  with  nicorandil  at  discharge  is  associated  wi
Although  details  of  the  mechanisms  are  unclear,  the  fol-
lowing  pharmacologic  and  other  properties  of  nicorandil  may
explain  why  this  drug  improves  survival  in  patients  with
CAD  or  AMI.  First,  cardioprotective  effects  exerted  by  nico-
randil  during  the  acute  stage  of  AMI  and/or  acute  myocardial
ischemia  [9—13,17,20—25]  may  have  also  provided  beneﬁts
in  the  convalescent  or  chronic  stages  of  AMI.  Second,  as  sug-
gested  in  the  J-WIND  study  [26], nicorandil  treatment  during
the  chronic  phase  of  AMI  may  have  improved  left  ventricu-
lar  function,  resulting  in  a  reduction  of  mortality.  Third,  the
positive  effects  of  nicorandil  on  sympathetic  nerve  activ-
ity  might  have  played  a  role  in  improving  survival.  Indeed,
although  it  was  a  small  sample-size  study  from  a  single  cen-
ter,  Kasama  et  al.  [18]  reported  that  the  long-term  (six
months)  administration  of  15  mg/dL  nicorandil  resulted  in
improved  cardiac  sympathetic  nerve  activity  in  AMI  patients.
Fourth,  the  anti-hypertensive  properties  of  nicorandil  might
have  reduced  long-term  mortality  [34]. As  discussed  previ-
ously,  nicorandil  appeared  to  have  been  prescribed  in  an
additive  manner  in  the  present  cohort,  rather  than  as  an
alternative  to  the  other  administered  cardioprotective  or
antihypertensive  drugs.  Accordingly,  the  adjunctive  use  of
nicorandil  may  have  lowered  blood  pressure  more  effec-
tively  than  in  the  control  group,  resulting  in  a  reduction
in  long-term  mortality.  Finally,  better  long-term  compliance
and  lack  of  tolerance  to  nicorandil  [35]  might  be  associated
with  improved  mortality.
In  the  present  study,  we  did  not  observe  signiﬁcant  reduc-
tions  in  other  cardiac  events  in  Group  N  patients,  unlike
the  results  from  the  IONA  study  [31]  and  JCAD  sub-study
[32].  This  discrepancy  may  have  been  due  to  differences  in
the  backgrounds  of  the  study  populations;  we  only  included
patients  who  survived  AMI  in  the  present  study,  whereas  the
other  two  studies  included  individuals  with  stable  angina
or  CAD  [31,32].  Accordingly,  it  appears  that  the  study
cohort  might  have  been  more  strictly  treated  with  sec-
ondary  prevention  medications  in  the  present  study,  as
the  prevalence  of  co-administered  cardioprotective  drugs
such  as  antiplatelets,  ACE  inhibitors,  angiotensin  II  recep-
tor  blockers  (ARBs),  -blockers,  and  statin  was  higher  than
or  at  least  equal  to  those  in  the  IONA  and  JCAD  studies
[31,32].  In  addition,  the  cohort  subjects  in  the  present
study  had  all  received  emergent  PCI  for  infarct  related
arteries  and  were  likely  to  have  undergone  subsequent
PCI  for  other  diseased  coronary  arteries  in  the  acute  or
convalescent  stage  of  AMI,  possibly  resulting  in  a  reduc-
tion  of  residual  myocardial  ischemia  and  prevention  of
ischemia-related  cardiovascular  complications.  Therefore,
the  beneﬁcial  effects  of  nicorandil  on  cardiovascular  events
other  than  mortality  may  have  been  masked  by  the  increased
usage  of  co-administered  cardioprotective  drugs,  as  well
as  differences  in  the  management  of  diseased  coronary
arteries.
A  few  limitations  of  the  study  warrant  mention.  First,
as  this  was  a  retrospective  observational  study,  precise
information  concerning  the  dose,  duration  and  patient  com-
pliance  for  nicorandil  treatment,  was  not  available.  In
addition,  information  about  cardiac  function  at  discharge
was  not  obtained  in  the  present  study.  Second,  as  it  was  also
observed  that  patients  in  Group  N  appeared  to  have  more
severe  clinical  CAD  conditions,  including  a  higher  incidence
of  multi-vessel  disease  and  a  lower  rate  of  successful  PCI,
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he overall  efﬁcacy  of  nicorandil  may  have  been  underesti-
ated.  Third,  the  present  study  enrolled  only  the  subjects
ho  underwent  emergent  PCI  in  the  acute  stage  of  AMI.
ccordingly,  caution  may  be  needed  when  interpreting  the
esults  for  AMI  patients  who  did  not  receive  emergent  PCI.
ourth,  although  the  results  suggested  that  nicorandil  was
ffective  to  reduce  mortality  in  those  with  age  of  <75  y.o.  or
hose  with  male  gender,  the  mechanisms  were  unclear  and
hus  remain  to  be  disclosed.
In  conclusion,  we  have  demonstrated  that  the  oral  admin-
stration  of  nicorandil  following  AMI  was  associated  with
educed  incidence  of  death  for  all  patients,  particularly  in
ndividuals  with  ages  <75  y.o.,  male  gender  and  hyperten-
ion.  Although  further  randomized  clinical  investigations  are
eeded,  the  promising  clinical  outcomes  presented  here  sug-
est  that  nicorandil  on  oral  administration  may  be  effective
or  treating  CAD  and  is  expected  to  improve  patient  survival
n  the  secondary  prevention  setting  following  AMI.
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